INCUBATION CHAMBERS MADE OF PLASTIC.

V. Bartonícek,Z. Lojda

IF: 2.147

1963-06-30

Acta Histochemica

Abstract:

What problem does this paper attempt to address?

High expression of the classical swine fever virus (CSFV) envelope protein E2 by a single amino acid mutation and its embedded in the pseudorabies virus (PRV) vector for immunization

Tao Yun,Zheng Ni,Liu Chen,Cun Zhang,Yang-yang Sun,Ke-shu Liu,Yin-chu Zhu,Hai-li Bao,Wei-cheng Ye,Jiong-gang Hua,Su-xin Huo,Hong-yu Wang,En-dong Bao

DOI: https://doi.org/10.1016/j.virusres.2023.199111

IF: 6.286

2023-04-26

Virus Research

Abstract:Pseudorabies (PR) and classical swine fever (CSF) are economically important infectious diseases in pigs. Most pig farms in China are vaccinated against these two diseases. Gene-deleted pseudorabies virus (PRV) can be used to develop promising and economical multivalent live attenuated viral vector vaccines. It has been reported that recombinant PRV can express a truncated E2 protein (1–338 aa), but it has not been reported that recombinant PRV can express a full-length E2 protein. We constructed nine groups of E2 proteins with different expression forms and found that the E2 protein could be expressed in vitro only when the transmembrane region of E2 was removed and the signal peptide was added. Analysis of the transmembrane region of E2 revealed that the high hydrophobicity of the E2 transmembrane region was the main reason for its inability to express. By mutating an amino acid to reduce the hydrophobicity of the transmembrane region, it was found that the full-length mutant of E2 (E2FL-muta3 or E2FL-muta4) could be expressed. The expressed full-length mutant E2 could also localize to the cell membrane. Mice immunized with a PRV vector vaccine expressing E2FL-muta3 or E2FL-muta4 developed specific cellular immunity to the E2 protein and stimulated higher levels of E2 antibody than mice immunized with a PRV vector expressing truncated E2. After immunizing the rabbits, the lethal challenge by PRV-ZJ2013 and the febrile response elicited by CSFV were simultaneously prevented. These results suggest that rPRV-dTK/gE-E2FL-muta4 is a promising bivalent vaccine against CSFV and PRV infections.

virology
Generation and immunogenicity analysis of recombinant classical swine fever virus glycoprotein E2 and Erns expressed in baculovirus expression system

Qiang Wei,Yilin Bai,Yapeng Song,Yunchao Liu,Wei Yu,Yaning Sun,Li Wang,Ruiguang Deng,Guangxu Xing,Gaiping Zhang

DOI: https://doi.org/10.1186/s12985-021-01507-1

IF: 5.916

2021-02-24

Virology Journal

Abstract:Abstract Classical swine fever (CSF) caused by the classical swine fever virus (CSFV) is a highly contagious swine disease resulting in large economical losses worldwide. The viral envelope glycoprotein E2 and E rns are major targets for eliciting antibodies against CSFV in infected animals. In this report, the glycoprotein E2 and E rns were expressed using the baculovirus system and their protective immunity in rabbits were tested. Twenty CSFV seronegative rabbits were randomly divided into five groups. Each rabbit was intramuscularly immunized with CSFV-E2, CSFV-E rns , or their combination (CSFV-E2 + E rns ). Besides, a commercial CSFV vaccine (C-strain) and PBS were used as positive or negative controls, respectively. Four weeks after the second immunization, all the rabbits were challenged with 100 RID 50 of CSFV C-strain. High levels of CSFV E2-specific antibody, neutralizing antibody and cellular immune responses to CSFV were elicited in the rabbits inoculated with C-strain, CSFV-E2, and CSFV-E2 + E rns . And the rabbits inoculated with the three vaccines received complete protection against CSFV C-strain. However, no neutralizing antibody was detected in the E rns vaccinated rabbits and the rabbits exhibited fever typical of CSFV, suggesting the E rns alone is not able to induce a protective immune response. Taken together, while the E rns could not confer protection against CSFV, E2 and E2 + E rns could not only elicit humoral and cell-mediated immune responses but also confer complete protection against CSFV C-strain in rabbits.

virology
Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Huiling Xu,Yanli Wang,Guangwei Han,Weihuan Fang,Fang He

DOI: https://doi.org/10.21203/rs.2.18234/v1

2019-01-01

Abstract:Background: Outbreaks of CSFV cause significant economic losses in the swine industry. Subunit vaccines present advantages in DIVA immunogenicity and safety. The technology was limited due to the low yield and the high cost with multiple and large doses. Results: A novel E2 sequence (E2ZJ) was identified from an epidemic strain of Zhejiang for outstanding secretion in baculovirus and enhanced immunogenicity. E2 secretion induced with the selected signal peptide, SPZJ, increase at least 50% as compared to any other signal peptides tested. Besides, unique antigenic features were identified in E2ZJ. E2ZJ elicited CSFV antibody at the earlier stage than other E2 types tested in mice. Meantime, higher level of neutralization antibody with E2ZJ was detected than other E2s at the same dosage. Further, in piglets, E2ZJ successfully elicited neutralizing immunity. A single dose of 5 μg of E2ZJ was sufficient to induce protective antibody against CSFV in piglets and provided 100% protection against lethal virus challenge. Conclusions: In this study, with advantages in secretion and immunogenicity over counterparts, SPZJ-E2ZJ is a cost-effective and efficacious vaccine candidate against CSFV. Keywords: Classical swine fever virus; novel signal peptide; SPZJ-E2ZJ; subunit vaccine; protective immunity
E2 and E rns of classical swine fever virus C-strain play central roles in its adaptation to rabbits

Tong Cao,Zuohuan Wang,Xiaoye Li,Shengnan Zhang,Narayan Paudyal,Xian Zhang,Xiaoliang Li,Weihuan Fang

DOI: https://doi.org/10.1007/s11262-018-01631-1

2019-01-01

Virus Genes

Abstract:The classical swine fever virus (CSFV) C-strain has been used as a vaccine strain for over 60 years in China. A recent study has demonstrated that the E2 protein of C-strain plays a major role in its adaptation to rabbits. E2 protein in combination with either E rns or E1 confers rabbit adaptation for the C-strain, and the residues P108 and T109 in domain I of E2 are critical for rabbit adaptation. To further identify the contributions of the glycoproteins to rabbit adaptation, a series of C-strain-based chimeric viruses containing single or double glycoprotein substitutions of the Shimen strain were generated and inoculated into rabbits. Profiles of rectal temperature, viral RNA, E2 protein expression, and antibody responses were compared among the chimeric viruses. Replacement of E rns , E2, E rns –E2, or E1–E2 of the C-strain with the counterpart(s) of the Shimen strain led to decreased fever response, reduction of viral RNA and antibody responses in rabbits, as compared with their parental C-strain. The C-strain-based chimeric virus expressing the Shimen strain E1 exhibited typical fever response and viral RNA level similar to the C-strain. However, substitution of both E rns and E2 in the C-strain backbone abolished fever response, and the chimeric virus did not show adaptation in rabbits as demonstrated by lack of viral RNA and E2 protein expression in the spleen and weak antibody responses. These results indicate that E rns has partial contribution to adaptation of the C-strain in rabbits, and combination of E2 and E rns is essential for the C-strain to have adaptive replication in rabbits.
Safety and Immunogenicity of a Ge/gi/tk Gene-Deleted Pseudorabies Virus Variant Expressing the E2 Protein of Classical Swine Fever Virus in Pigs.

Jian-Lin Lei,Shui-Li Xia,Yimin Wang,Mingliang Du,Guang-Tao Xiang,Xin Cong,Yuzi Luo,Lian-Feng Li,Lingkai Zhang,Jiahui Yu,Yonghao Hu,Hua-Ji Qiu,Yuan Sun

DOI: https://doi.org/10.1016/j.imlet.2016.04.014

IF: 4.23

2016-01-01

Immunology Letters

Abstract:Classical swine fever (CSF) and pseudorabies (PR) are both major infectious diseases of pigs, causing enormous economic losses to the swine industry in many countries. A marker vaccine that enables differentiation of infected from vaccinated animals (DIVA) is highly desirable for control and eradication of these two diseases in endemic areas. Since late 2011, PR outbreaks have been frequently reported in many Bartha-K61-vaccinated pig farms in China. It has been demonstrated that a pseudorabies virus (PRV) variant with altered antigenicity and increased pathogenicity was responsible for the outbreaks. Previously, we showed that rPRVTJ-delgE/gI/TK, a gE/gI/TK-deleted PRV variant, was safe for susceptible animals and provided a complete protection against lethal PRV variant challenge, indicating that rPRVTJ-delgE/gI/TK can be used as an attractive vaccine vector. To develop a safe bivalent vaccine against CSF and PR, we generated a recombinant virus rPRVTJ-delgE/gI/TK-E2 expressing the E2 protein of classical swine fever virus (CSFV) based on rPRVTJ-delgE/gI/TK and evaluated its safety and immunogenicity in pigs. The results indicated that pigs (n=5) immunized with rPRVTJ-delgE/gI/TK-E2 of different doses did not exhibit clinical signs or viral shedding following immunization, the immunized pigs produced anti-PRV or anti-CSFV neutralizing antibodies and the pigs immunized with 106 or 105 TCID50 rPRVTJ-delgE/gI/TK-E2 were completely protected against the lethal challenge with either CSFV Shimen strain or variant PRV TJ strain. These findings suggest that rPRVTJ-delgE/gI/TK-E2 is a promising bivalent DIVA vaccine candidate against CSFV and PRV coinfections.
Construction of a Chimeric Classical Swine Fever Virus C-strain Containing E2 of Group Ⅱ Isolate Remains and Its Biological Characteristics

童超,陈宁,廖迅,袁雪梅,李肖梁,方维焕

DOI: https://doi.org/10.3864/j.issn.0578-1752.2013.01.021

2013-01-01

Abstract:Objective) The classical swine fever (CSF) C-strain vaccine has proven to be safe and highly efficacious. However, classical swine fever virus (CSFV) genotype Ⅱisolates became dominant in recent years, making it more challenging to bring the disease into total control. This study was attempted to engineer, by reverse genetic approach, a novel C-strain-based vaccine candidate that matches molecular variations of field isolates, and to characterize its biological features. Those results could provide foundations for further development of a marker vaccine for differential diagnostic purpose.(Method)An infectious recombinant CSF virus was generated by exchanging the 5'-end 870-bp of E2 gene in C-strain with the same fragment from group 2 strain HZ1-08. The resulting recombinant virus RecCHZE2 was rescued and its pathogenicity and immunogenicity were characterized in rabbits and pigs. (Result) Rabbits inoculated with RecCHZE2 exhibited typical temperature profiles similar to the C-strain with spleen enlargement. Pigs inoculated with the recombinant chimeric virus did not show fever and significant decline of the number of white blood cells. Mild transient viremia was detected at day 12 post-inoculation. The antibody responses specific to the field strain HZ1-08 reached the peak 20 days post-inoculation. The neutralizing antibody titers from pigs immunized with RecCHZE2 were similar to both HZ1-08 and C strains while the titer from pigs immunized with RecC were lower for group 2 strain HZ1-08.(Conclusion) The recombinant virus RecCHZE2 remains avirulent but differs in immunogenic properties from the C-strain.
Expression of E2 Protein of Classical Swine Fever Virus Shimen Strain Using Baculovrius Expression System

Xiang-yang ZHOU,Jing WAN,Xun LIAO,Zhu-jun ZHU,Xiao-wei CHEN,Fei-fen LIU,Wei-huan FANG

DOI: https://doi.org/10.3969/j.issn.1007-5038.2012.01.006

2012-01-01

Abstract:Expression of E2 protein of CSFV Shimen strain in baculovirus Bac-to-Bac expression system provided materials for research of the function of E2 protein and develope novel vaccine against CSFV.E2 gene of CSFV Shimen strain was subcloned into a baculovirus transfer vector pFastBacHTA to yield the recombinant transfer plasmid pFastBacHTA-E2.Recombinant bacmid was obtained after transforming the E.coli DH10Bac competent cells.Subsequently,the recombinant bacmid was transfected into Sf9 cells,then got the recombinant virus.The expressed recombinant protein was analyzed by Western blot and indirect immunofluorescence test.The results indicated that E2 protein was efficiently expressed,and had a specific reaction with monoclonal antibody 2B10 and 6×His monoclonal antibody.The E2 protein of CSFV Shimen strain was successfully expressed in Sf9 cells,and had a good antigenicity.
Continuous Passaging of A Recombinant C-Strain Virus in Pk-15 Cells Selects Culture-Adapted Variants That Showed Enhanced Replication but Failed to Induce Fever in Rabbits

Chao Tong,Ning Chen,Xun Liao,Xuemei Yuan,Mengjiao Sun,Xiaoliang Li,Weihuan Fang

DOI: https://doi.org/10.4014/jmb.1704.04065

2017-01-01

Journal of Microbiology and Biotechnology

Abstract:Classical swine fever virus (CSFV) is the etiologic agent of classical swine fever, a highly contagious disease that causes significant economic losses to the swine industry. The lapinized C-strain, a widely used vaccine strain against CSFV, has low growth efficiency in cell culture, which limits the productivity in the vaccine industry. In this study, a recombinant virus derived from C-strain was constructed and subjected to continuous passaging in PK-15 cells with the goal of acquiring a high progeny virus yield. A cell-adapted virus variant, RecCpp80, had nearly 1,000-fold higher titer than its parent C-strain but lost the ability to induce fever in rabbits. Sequence analysis of cell-adapted RecC variants indicated that at least six nucleotide changes were fixed in RecCpp80. Further adaption of RecCpp80 variant in swine testicle cells led to a higher virus yield without additional mutations. Introduction of each of these residues into the wild-type RecC backbone showed that one mutation, M979R (T3310G), located in the C-terminal region of E2 might be closely related to the cell-adapted phenotype. Rabbit inoculation revealed that RecCpp80(+10) failed to induce fever in rabbits, whereas RecCpp40(+10) caused a fever response similar to the commercial C-strain vaccine. In conclusion, the C-strain can be adapted to cell culture by introducing specific mutations in its E2 protein. The mutations in RecCpp80 that led to the loss of fever response in rabbits require further investigation. Continuous passaging of the C-strain-based recombinant viruses in PK-15 cells could enhance its in vitro adaption. The non-synonymous mutations at 3310 and 3531 might play major roles in the enhanced capacity of general virus reproduction. Such findings may help design a modified C-strain for improved productivity of commercial vaccines at reduced production cost.
Immune duration of a recombinant PRRSV vaccine expressing E2 of CSFV

Fei Gao,Yifeng Jiang,Guoxin Li,Yujiao Zhang,Kuan Zhao,Haojie Zhu,Liwei Li,Lingxue Yu,Hao Zheng,Yanjun Zhou,Wu Tong,Guangzhi Tong

DOI: https://doi.org/10.1016/j.vaccine.2020.10.057

IF: 4.169

2020-11-01

Vaccine

Abstract:Classical swine fever virus (CSFV) and Porcine reproductive and respiratory syndrome virus (PRRSV) are both important pathogens which seriously harm the economic swine industry worldwide. We have previously demonstrated that rPRRSV-E2 is a promising live, virus-vectored vaccine that provides 100% protection against highly pathogenic PRRSV (HP-PRRSV) and CSFV. Here, we evaluated the duration of immunity (DOI) of the vaccine strain, rPRRSV-E2. Vaccine or cell culture medium was administered to piglets at 4 weeks of age. All immunized piglets developed high levels of antibodies, which could maintain for up to 23 weeks, against PRRSV and CSFV. All immunized pigs were well protected from the challenge of HP-PRRSV or CSFV at 20 weeks and 24 weeks post vaccination. The vaccine protection rate was still 100% at 24 weeks after immunization. The immune efficacy results showed that the immune duration of rPRRSV-E2 could be up to 5 months.

immunology,medicine, research & experimental
Hypervariable Antigenic Region 1 of Classical Swine Fever Virus E2 Protein Impacts Antibody Neutralization.

Xun Liao,Zuohuan Wang,Tong Cao,Chao Tong,Shichao Geng,Yuanxing Gu,Yingshan Zhou,Xiaoliang Li,Weihuan Fang

DOI: https://doi.org/10.1016/j.vaccine.2016.06.007

IF: 4.169

2016-01-01

Vaccine

Abstract:Envelope glycoprotein E2 of classical swine fever virus (CSFV) is the major antigen that induces neutralizing antibodies and confers protection against CSFV infection. There are three hypervariable antigenic regions (HAR1, HAR2 and HAR3) of E2 that are different between the group 1 vaccine C-strain and group 2 clinical isolates. This study was aimed to characterize the antigenic epitope region recognized by monoclonal antibody 4F4 (mAb-4F4) that is present in the group 2 field isolate HZ1-08, but not in the C-strain, and examine its impact on neutralization titers when antisera from different recombinant viruses were cross-examined. Indirect ELISA with C-strain E2-based chimeric proteins carrying the three HAR regions showed that the mAb-4F4 bound to HAR1 from HZ1-08 E2, but not to HAR2 or HAR3, indicating that the specific epitope is located in the HAR1 region. Of the 6 major residues differences between C-strain and field isolates, Glu713 in the HAR1 region of strain HZ1-08 is critical for mAb-4F4 binding either at the recombinant protein level or using intact recombinant viruses carrying single mutations. C-strain-based recombinant viruses carrying the most antigenic part of E2 or HAR1 from strain HZ1-08 remained non-pathogenic to pigs and induced good antibody responses. By cross-neutralization assay, we observed that the anti-C-strain serum lost most of its neutralization capacity to RecC-HZ-E2 and QZ-14 (subgroup 2.1d field isolate in 2014), and vice versa. More importantly, the RecC-HAR1 virus remained competent in neutralizing ReC-HZ-E2 and QZ-14 strains without compromising the neutralization capability to the recombinant C-strain. Thus, we propose that chimeric C-strain carrying the HAR1 region of field isolates is a good vaccine candidate for classical swine fever.
Recombinant Bivalent Live Vectored Vaccine Against Classical Swine Fever and HP-PRRS Revealed Adequate Heterogeneous Protection Against NADC30-Like Strain

Liwei Li,Jinxia Chen,Zhengda Cao,Yunlei Cao,Ziqiang Guo,Wu Tong,Yanjun Zhou,Guoxin Li,Yifeng Jiang,Changlong Liu,Lingxue Yu,Sina Qiao,Jiachen Liu,Guangzhi Tong,Fei Gao

DOI: https://doi.org/10.3389/fmicb.2021.822749

IF: 5.2

2022-01-05

Frontiers in Microbiology

Abstract:The recombinant bivalent live vectored vaccine rPRRSV-E2 has been proved to be a favorable genetic engineering vaccine against classical swine fever (CSF) and highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS). NADC30-like strains have recently emerged in China and caused severe disease, and it is necessary to evaluate the vaccine candidate for the currently circulating viruses. This study established a good challenge model to evaluate the candidate rPRRSV-E2 vaccine in preventing infection with a representative NADC30-like strain (ZJqz21). It was shown that the challenge control piglets displayed clinical signs typical of PRRSV, including a persistent fever, dyspnea, moderate interstitial pneumonia, lymph node congestion, and viremia. In contrast, the rPRRSV-E2 vaccination significantly alleviated the clinical signs, yielded a high level of antibodies, provided adequate protection against challenge with ZJqz21, and inhibited viral shedding and the viral load in target tissues. Our results demonstrated that the recombinant bivalent live vectored vaccine strain rPRRSV-E2 can provide efficient protection against the challenge of heterologous circulating NADC30-like strain and could be a promising vaccine candidate for the swine industry.

microbiology
Construction of recombinant pseudorabies virus expressing PCV2 Cap, PCV3 Cap, and IL-4: investigation of their biological characteristics and immunogenicity

Yanting Yang,Zhiwen Xu,Qian Tao,Lei Xu,Sirui Gu,Yao Huang,Zheyan Liu,Yang Zhang,Jianhua Wen,Siyuan Lai,Ling Zhu

DOI: https://doi.org/10.3389/fimmu.2024.1339387

IF: 7.3

2024-03-20

Frontiers in Immunology

Abstract:Background Porcine circovirus type 2 (PCV2) is a globally prevalent and recurrent pathogen that primarily causes slow growth and immunosuppression in pigs. Porcine circovirus type 3 (PCV3), a recently discovered virus, commonly leads to reproductive disorders in pigs and has been extensively disseminated worldwide. Infection with a single PCV subtype alone does not induce severe porcine circovirus-associated diseases (PCVD), whereas concurrent co-infection with PCV2 and PCV3 exacerbates the clinical manifestations. Pseudorabies (PR), a highly contagious disease in pigs, pose a significant threat to the swine industry in China. Methods In this study, recombinant strains named rPRV-2Cap/3Cap and rPRV-2Cap/3Cap/IL4 was constructed by using a variant strain XJ of pseudorabies virus (PRV) as the parental strain, with the TK/gE/gI genes deleted and simultaneous expression of PCV2 Cap, PCV3 Cap, and IL-4. The two recombinant strains obtained by CRISPR/Cas gE gene editing technology and homologous recombination technology has genetic stability in baby hamster Syrian kidney-21 (BHK-21) cells and is safe to mice. Results rPRV-2Cap/3Cap and rPRV-2Cap/3Cap/IL4 exhibited good safety and immunogenicity in mice, inducing high levels of antibodies, demonstrated 100% protection against the PRV challenge in mice, reduced viral loads and mitigated pathological changes in the heart, lungs, spleen, and lymph nodes during PCV2 challenge. Moreover, the recombinant viruses with the addition of IL-4 as a molecular adjuvant outperformed the non-addition group in most indicators. Conclusion rPRV-2Cap/3Cap and rPRV-2Cap/3Cap/IL4 hold promise as recombinant vaccines for the simultaneous prevention of PCV2, PCV3, and PRV, while IL-4, as a vaccine molecular adjuvant, effectively enhances the immune response of the vaccine.

immunology
Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Chao Tong,Huanhuan Liu,Jiaying Wang,Yanyong Sun,Ning Chen

DOI: https://doi.org/10.1016/j.vaccine.2022.10.035

IF: 4.169

2022-01-01

Vaccine

Abstract:Classical swine fever virus (CSFV) is the etiological agent of classical swine fever, a highly contagious dis-ease that causes significant economic losses to the swine industry. Systemic prophylactic immunization with the live attenuated vaccine, the C-strain vaccine, is one of the effective measures for CSF control. However, one of the limitations of the C-strain vaccine is that the field strains-infected animals cannot be differentiated from the C-strain vaccinated herds by serological tests (DIVA). This constraint hampers the practical usage of the C-strain vaccine to eradicate the CSF in China. In the current study, a novel CSF modified live marker vaccine candidate was constructed based on the attenuation of the prevalent 2.1 genotype strain by the deletion of two virulence associated functional residues in the CSFV Erns, H79, and C171. Meanwhile, four residues S14, G22, E24, and E25 were identified specifically for the 6B8 mAb binding to the CSFV E2 as the novel conformational epitope. Then four substitutions of S14K, G22A, E24R, and G25D were further incorporated in the double deletion construct as a negative serolog-ical marker. Finally, the double-deletion marker MLV candidate GD18-ddErnHC-KARD was rescued, and its safety and efficacy profiles were evaluated in piglets. The safety study results indicated that the can-didate did not induce fever, clinical signs, or pathological lesions with a high dose of 105.0 TCID50, and in addition, no virus shedding was detected until 21 days post-inoculation. Meanwhile, the efficacy study results demonstrated that at a low dose of 103.0 TCID50, it conferred complete clinical protection and no virus shedding was detected after the challenge with a highly virulent Shimen strain. Importantly, the infected animals were differentiated using the accompanied DIVA ELISA. These results constitute a proof-of-concept for rationally designing a CSF antigenically marked modified live vaccine candidate.(c) 2022 Elsevier Ltd. All rights reserved.
Hyperbrain network properties of guitarists playing in quartet

Viktor Müller,Johanna C. Sänger,U. Lindenberger

DOI: https://doi.org/10.1111/nyas.13656

IF: 6.499

2018-07-01

Annals of the New York Academy of Sciences

Abstract:When playing music in an ensemble, musicians need to precisely coordinate their actions with one another. As shown in our previous studies on guitar duets, interbrain synchronization plays an essential role during such interactions. In this study, we simultaneously recorded electroencephalograms from four guitarists during quartet playing, to explore the extent and the functional significance of synchronized cortical activity across four brains. We found that hyperbrain networks based on intra‐ and interbrain connectivity across four brains dwell on higher frequencies for intrabrain communication and on lower frequencies for interbrain connections. The hyperbrain networks show small‐world topology, with a tendency to become more random at lower frequencies and more regular at higher frequencies, such that local efficiency increases and global efficiency decreases with higher frequencies. We identified two different types of information flow within the hyperbrain networks—intra‐ versus intermodular—which are based on hyperbrain modules that include nodes from two, three, or even four brains. Furthermore, we found that hyperbrain networks are unstable and change their structure over time, often as a function of musical context. Our findings demonstrate complex hyperbrain network interactions in a guitar quartet and point to mechanisms that support temporally coordinated joint action.
A novel Pseudorabies virus vaccine developed using HDR-CRISPR/Cas9 induces strong humoral and cellular immune response in mice

Chen Luo,Qianqian Wang,Ruhai Guo,Jingnan Zhang,Jingya Zhang,Riteng Zhang,Xin Ma,Peixin Wang,Fathalrhman Eisa Addoma Adam,Basit Zeshan,Zengqi Yang,Yefei Zhou,Xinglong Wang

DOI: https://doi.org/10.1016/j.virusres.2022.198937

IF: 6.286

2022-12-01

Virus Research

Abstract:Outbreaks of Pseudorabies (PR) by numerous highly virulent and antigenic variant Pseudorabies virus (PRV) strains have been causing severe economic losses to the pig industry in China since 2011. However, current commercial vaccines are often unable to induce thorough protective immunity. In this study, a TK/gI/gE deleted recombinant PRV expressing GM-CSF was developed by using the HDR-CRISPR/Cas9 system. Here, a four-sgRNA along with the Cas9D10A targeting system was utilized for TK/gI/gE gene deletion and GM-CSF insertion. Our study showed that the four-sgRNA targeting system appeared to have higher knock-in efficiency for PRVs editing. The replication of the recombinant PRVs were slightly lower than that of the parental strain, but they appeared to have similar properties in terms of growth curves and plaque morphology. The mice vaccinated with the recombinant PRV expressing GM-CSF via intramuscular injection showed no obvious clinical symptoms, milder pathological lesions, and were completely protected against wild-type PRV challenge. When compared to the triple gene-deleted PRV, the gB antibodies and neutralizing antibody titers were improved and the immunized mice appeared to have lower viral load and higher mRNA levels of IL-2, IL-4, IL-6, and IFN-γ in spleens. Our study offers a novel approach for recombinant PRV construction, and the triple gene-deleted PRV expressing GM-CSF could serve as a promising vaccine candidate for PR control.

virology
Bioprocess optimization for biomass production of probiotics yeast Saccharomyces boulardii in semi-industrial scale.

T. Chin,N. Othman,R. Malek,Nagib A. Elmarzugi,Leng OngMei,Solleh Ramli,N. Musa,R. Aziz,H. El-Enshasy

Abstract:Saccharomyces boulardii is non-pathogenic probiotic yeast with many health benefits. In the present wo rk, studies were carried out to improve cell growth kinetics to produce cell mass of this biotherapeutic yeast in semi-industrial scale. At first, five different media were screened to select the most appropriate formula for biomass production. The medium which yielded highest cell mass of 2.57 g L -1 and lowest ethanol was selected and further optimi zed by changing the concentrations of each component. The optimized medium composed of (g L ): Glucose, 20; Corn steep liquor, 15; NaNO 3, 1.0; KH2PO4, 6.0; MgSO4.7H20, 3.0; CuSO4.5H20, 0.002; FeSO4.7H20, 0.001; ZnSO4.7H20, 0.01 was then used for yeast biomass production in a pilot scale 16-L bioreactor in batch culture under controlled and uncontrolled pH. The highest b iomass of 8.2 g L -1 was achieved in pH controlled culture. This was almost double of the biomass obtained in shake fl sk. In conclusion, production process has been d eveloped for high cell mass production of the biotherapeutic yea st S. boulardii in semi-industrial scale.
Construction and immunogenicity of a gE/gI/TK-deleted PRV based on porcine pseudorabies virus variant

Yu Zhao,Lin-Qing Wang,Hui-Hua Zheng,Yu-Rong Yang,Fang Liu,Lan-Lan Zheng,Yue Jin,Hong-Ying Chen

DOI: https://doi.org/10.1016/j.mcp.2020.101605

IF: 3.285

2020-10-01

Molecular and Cellular Probes

Abstract:Pseudorabies (PR) caused by re-emerging pseudorabies virus (PRV) variant has outbroken among PRV vaccine-immunized swine herds on many Chinese pig farms, with severe socioeconomic consequences since late 2011. Here, a gE/gI/TK-deleted recombinant virus (rPRV NY-gE-/gI−/TK−) was constructed based on PRV NY strain from 2012 through homologous DNA recombination and gene-editing technology termed clustered regularly interspaced palindromic repeats (CRISPR)/associated (Cas9) system. The rPRV NY-gE-/gI−/TK− strain showed similar growth kinetics to the parental PRV NY strain in vitro, and was safe for mice. Sixty mice were injected subcutaneously (s.c.) twice with 106.0 TCID50 of rPRV NY-gE-/gI−/TK− and DMEM, respectively, with two-week interval. The levels of PRV gB antibodies and neutralizing antibodies against PRV NY in mice immunized with rPRV NY-gE-/gI−/TK− were higher than those in the DMEM control group. The number of T lymphocyte subclasses CD3+, CD4+ and CD8+ in rPRV NY-gE-/gI−/TK−-immunized mice was higher than that in DMEM-injected mice. After challenge with 106.0 TCID50 PRV NY at 42 dpi, all rPRV NY-gE-/gI−/TK−-immunized mice survived without exhibiting any pathological lesions in different tissues and intranuclear eosinophilic inclusions of the brain, and the viral genomic copy numbers in various organs of mice were obviously lower than DMEM group. These results showed the rPRV NY-gE-/gI−/TK− could be a promising next-generation vaccine to control now epidemic PR in China.

cell biology,biochemistry & molecular biology,biochemical research methods,biotechnology & applied microbiology
An Expeditious Neutralization Assay for Porcine Reproductive and Respiratory Syndrome Virus Based on a Recombinant Virus Expressing Green Fluorescent Protein

Juan Wang,Jiecong Yan,Shuaiyong Wang,Ronglin Chen,Yanru Xing,Qingyan Liu,Shuolei Gao,Yuxiang Zhu,Jiannan Li,Yanjun Zhou,Tongling Shan,Wu Tong,Hao Zheng,Ning Kong,Yifeng Jiang,Changlong Liu,Guangzhi Tong,Hai Yu

DOI: https://doi.org/10.3390/cimb46020066

2024-01-23

Current Issues in Molecular Biology

Abstract:Due to the extensive genetic and antigenic variation in Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), as well as its rapid mutability and evolution, PRRS prevention and control can be challenging. An expeditious and sensitive neutralization assay for PRRSV is presented to monitor neutralizing antibodies (NAbs) in serum during vaccine research. Here, a PRRSV expressing eGFP was successfully rescued with reverse genetics based on the infectious clone HuN4-F112-eGFP which we constructed. The fluorescent protein expressions of the reporter viruses remained stable for at least five passages. Based on this reporter virus, the neutralization assay can be easily used to evaluate the level of NAbs by counting cells with green fluorescence. Compared with the classical CPE assay, the newly developed assay increases sensitivity by one- to four-fold at the early antibody response stage, thus saving 2 days of assay waiting time. By using this assay to unveil the dynamics of neutralizing antibodies against PRRSV, priming immunity through either a single virulent challenge or only vaccination could produce limited NAbs, but re-infection with PRRSV would induce a faster and stronger NAb response. Overall, the novel HuN4-F112-eGFP-based neutralization assay holds the potential to provide a highly efficient platform for evaluating the next generation of PRRS vaccines.

biochemistry & molecular biology
Development and immunogenicity evaluation of a quadruple-gene-deleted pseudorabies virus strain

Hui Li,Riteng Zhang,Jiahao Qu,Yahao Kang,Jingnan Zhang,Ruhai Guo,JunDa Li,Xiao Zhang,Likang Han,Honglin Xie,Xinglong Wang

DOI: https://doi.org/10.3389/fmicb.2024.1479794

2024-09-20

Abstract:Since 2011, the emergence of Pseudorabies virus (PRV) variants has led to significant vaccine failures, resulting in severe economic losses in China's swine industry. Conventional PRV vaccines have shown limited efficacy against these emergent variants, underscoring the urgent need for novel immunization strategies. This study aimed to develop and evaluate a novel recombinant PRV vaccine candidate with improved safety and immunogenicity profiles. Utilizing the homology-directed repair (HDR)-CRISPR/Cas9 system, we generated a recombinant PRV strain, designated PRV SX-10ΔgI/gE/TK/UL24, with deletions in the gI, gE, TK, and UL24 genes. In vitro analyses demonstrated that the recombinant virus exhibited similar replication kinetics and growth curves comparable to the parental strain. The immunological properties of the recombinant PRV were assessed in murine and porcine models. All animals inoculated with PRV SX-10ΔgI/gE/TK/UL24 survived without exhibiting significant clinical signs or pathological alterations. Immunological assays revealed that PRV SX-10ΔgI/gE/TK/UL24 elicited significantly higher levels of gB-specific antibodies, neutralizing antibodies, and cytokines (including IFN-γ, IL-2, and IL-4) compared to both the Bartha-K61 and PRV SX-10ΔgI/gE/TK strains. Notably, both murine and porcine subjects immunized with PRV SX-10ΔgI/gE/TK/UL24 demonstrated enhanced protection against challenges with the variant PRV SX-10 strain, compared to other vaccine strains. These findings suggest that PRV SX-10ΔgI/gE/TK/UL24 represents a promising PRV vaccine candidate strain, offering valuable insights for the prevention and control of PRV in clinical applications.
Immunological characteristics of a recombinant alphaherpesvirus with an envelope-embedded Cap protein of circovirus

Chenhe Lu,Haimin Li,Wenjing Chen,Hui Li,Jiayu Ma,Peng Peng,Yan Yan,Weiren Dong,Yulan Jin,Shiyue Pan,Shaobin Shang,Jinyan Gu,Jiyong Zhou

DOI: https://doi.org/10.3389/fimmu.2024.1438371

2024-07-16

Abstract:Introduction: Variant pseudorabies virus (PRV) is a newly emerged zoonotic pathogen that can cause human blindness. PRV can take advantage of its large genome and multiple non-essential genes to construct recombinant attenuated vaccines carrying foreign genes. However, a major problem is that the foreign genes in recombinant PRV are only integrated into the genome for independent expression, rather than assembled on the surface of virion. Methods: We reported a recombinant PRV with deleted gE/TK genes and an inserted porcine circovirus virus 2 (PCV2) Cap gene into the extracellular domain of the PRV gE gene using the Cre-loxP recombinant system combined with the CRISPR-Cas9 gene editing system. This recombinant PRV (PRV-Cap), with the envelope-embedded Cap protein, exhibits a similar replication ability to its parental virus. Results: An immunogenicity assay revealed that PRV-Cap immunized mice have 100% resistance to lethal PRV and PCV2 attacks. Neutralization antibody and ELISPOT detections indicated that PRV-Cap can enhance neutralizing antibodies to PRV and produce IFN-γ secreting T cells specific for both PRV and PCV2. Immunological mechanistic investigation revealed that initial immunization with PRV-Cap stimulates significantly early activation and expansion of CD69+ T cells, promoting the activation of CD4 Tfh cell dependent germinal B cells and producing effectively specific effector memory T and B cells. Booster immunization with PRV-Cap recalled the activation of PRV-specific IFN-γ+IL-2+CD4+ T cells and IFN-γ+TNF-α+CD8+ T cells, as well as PCV2-specific IFN-γ+TNF-α+CD8+ T cells. Conclusion: Collectively, our data suggested an immunological mechanism in that the recombinant PRV with envelope-assembled PCV2 Cap protein can serve as an excellent vaccine candidate for combined immunity against PRV and PCV2, and provided a cost-effective method for the production of PRV- PCV2 vaccine.

INCUBATION CHAMBERS MADE OF PLASTIC.

High expression of the classical swine fever virus (CSFV) envelope protein E2 by a single amino acid mutation and its embedded in the pseudorabies virus (PRV) vector for immunization

Generation and immunogenicity analysis of recombinant classical swine fever virus glycoprotein E2 and Erns expressed in baculovirus expression system

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

E2 and E rns of classical swine fever virus C-strain play central roles in its adaptation to rabbits

Safety and Immunogenicity of a Ge/gi/tk Gene-Deleted Pseudorabies Virus Variant Expressing the E2 Protein of Classical Swine Fever Virus in Pigs.

Construction of a Chimeric Classical Swine Fever Virus C-strain Containing E2 of Group Ⅱ Isolate Remains and Its Biological Characteristics

Expression of E2 Protein of Classical Swine Fever Virus Shimen Strain Using Baculovrius Expression System

Continuous Passaging of A Recombinant C-Strain Virus in Pk-15 Cells Selects Culture-Adapted Variants That Showed Enhanced Replication but Failed to Induce Fever in Rabbits

Immune duration of a recombinant PRRSV vaccine expressing E2 of CSFV

Hypervariable Antigenic Region 1 of Classical Swine Fever Virus E2 Protein Impacts Antibody Neutralization.

Recombinant Bivalent Live Vectored Vaccine Against Classical Swine Fever and HP-PRRS Revealed Adequate Heterogeneous Protection Against NADC30-Like Strain

Construction of recombinant pseudorabies virus expressing PCV2 Cap, PCV3 Cap, and IL-4: investigation of their biological characteristics and immunogenicity

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Hyperbrain network properties of guitarists playing in quartet

A novel Pseudorabies virus vaccine developed using HDR-CRISPR/Cas9 induces strong humoral and cellular immune response in mice

Bioprocess optimization for biomass production of probiotics yeast Saccharomyces boulardii in semi-industrial scale.

Construction and immunogenicity of a gE/gI/TK-deleted PRV based on porcine pseudorabies virus variant

An Expeditious Neutralization Assay for Porcine Reproductive and Respiratory Syndrome Virus Based on a Recombinant Virus Expressing Green Fluorescent Protein

Development and immunogenicity evaluation of a quadruple-gene-deleted pseudorabies virus strain

Immunological characteristics of a recombinant alphaherpesvirus with an envelope-embedded Cap protein of circovirus